Skip to main content Back to Top
Advertisement

8/28/2019

Hepatitis A Virus Vaccine Inactivated

Products Affected - Description

    • Havrix Adult intramuscular suspension for injection, GlaxoSmithKline Vaccines, 1440 EL.U., 1 mL single dose vial, 10 count, NDC 58160-0826-11 - discontinued
    • Havrix Pediatric intramuscular suspension for injection, GlaxoSmithKline Vaccines, 720 EL.U., 0.5 mL single dose vial, 10 count, NDC 58160-0825-11 - discontinued
    • Vaqta Adult intramuscular suspension for injection, Merck, 50U, 1 mL single dose vial, 1 count, NDC 00006-4841-00 - discontinued

Reason for the Shortage

    • Merck has Vaqta available.
    • Merck discontinued Vaqta adult formulation 50 U/1 mL vials in 1 count in January 2019.
    • GlaxoSmithKline has Havrix availablee.
    • GlaxoSmithKline discontinued the Havrix pediatric vials in March 2019. The Havrix adult vials were discontinued in November 2017.

Available Products

    • Havrix Adult intramuscular suspension for injection, GlaxoSmithKline Vaccines, 1440 EL.U., 1 mL prefilled syringe, 10 count, NDC 58160-0826-52
    • Havrix Pediatric intramuscular suspension for injection, GlaxoSmithKline Vaccines, 720 EL.U., 0.5 mL prefilled syringe, 10 count, NDC 58160-0825-52
    • Vaqta Adult intramuscular suspension for injection, Merck, 50U, 1 mL single-dose prefilled Luer Lock syringe, 10 count, NDC 00006-4096-02
    • Vaqta Adult intramuscular suspension for injection, Merck, 50U, 1 mL single dose vial, 10 count, NDC 00006-4841-41
    • Vaqta Pediatric/Adolescent intramuscular suspension for injection, Merck, 25U, 0.5 mL single-dose prefilled Luer Lock syringe, 10 count, NDC 00006-4095-02
    • Vaqta Pediatric/Adolescent intramuscular suspension for injection, Merck, 25U, 0.5 mL single dose vial, 10 count, NDC 00006-4831-41

Updated

Updated August 28, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created December 13, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins